Peter Barrett-Lee has a leading role for breast cancer academic scientific research at Velindre NHS Trust, The Rutherford Cancer Centre and at the College of Life Sciences, Cardiff University. The Velindre Cancer Centre based in North Cardiff provides specialist cancer services to over 1.5 million people living in South East Wales.
Peter’s NHS practice based at the Velindre Cancer Centre includes clinical trials research and he is a past member of the UK NCRI Breast Group (elected 2004), where he also helped develop and present national guidelines for the monitoring and management of cardiac effects from the use of adjuvant trastuzumab (Herceptin) therapy. He was elected Chair of the UK Breast Cancer Intergroup (2009-12) charged by the NCRI with developing the next generation of clinical trials in the UK. He has been Co-Principal Investigator on three large UK trials with nearly 10,000 patients randomised (TACT, TACT2, ZICE). He is member and Past Secretary of the British Breast Group, a national multidisciplinary society running scientific meetings twice annually and whose membership includes many of the scientific and clinical leaders in the field. In 2012, he became Professor of Breast Cancer Studies (2 sessions) at Cardiff University.
Peter stepped down as Medical Director of Velindre NHS Trust in 2017, having had responsibilities for both Divisions – Velindre Cancer Centre and The Welsh Blood Service including being the Responsible Officer since 2010. More recently, he has treated the first patients ever in the UK with Proton Beam Therapy for Breast Cancer at the Rutherford Cancer Centre, Newport. He has also been intimately involved with Innovation at Velindre, and is part of the team leading on their IBM/Watson Chatbot called RiTTa.